Excitingly, glypican-3 (GPC-3) can act as an anchoring carcinoembryonic proteoglycan on tumor cell membranes in combination with CAR-T technology to provide a new light for immunotherapy of solid tumors, especially HCC [53]. This evidence concerns the gene GPC3 and neoplasm.